Results

1–9 of 9 results for treat-and-extend

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Prospective Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: One-Year Outcomes
Amy C. Schefler, MD FACS FASRS
Annual Meeting Talks
2022
Management of Proliferative Vitreoretinopathy With Intravitreal Methotrexate Using a Treat-and-Extend Protocol
Scott D Walter, MD, MSc, FASRS
Annual Meeting Talks
2020
Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2020
Management of Proliferative Vitreoretinopathy with Intravitreal Methotrexate Using a Treat-and-Extend Protocol
Scott D Walter, MD, MSc, FASRS
Updates from the Field
2020
Treat-and-Extend Versus Bimonthly Dosing With Aflibercept for the Treatment of Diabetic Macular Edema, 1-Year Outcomes (EVADE Study)
Dilsher S. Dhoot, MD
Annual Meeting Talks
2018
Canadian Treat-and-Extend Analysis Trial With Ranibizumab in Patients With Neovascular AMD: CANTREAT Study 1-Year Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2018
Episode 23: CANTREAT Study. Ranibizumab Monthly vs Treat-and-Extend for wAMD with Dr. Peter Kertes
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019
Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients With Neovascular AMD: CANTREAT Study 1-Year Results
Peter J. Kertes, MD, FRCS(C)
Updates from the Field
2018